menu search

Morphic announces corporate highlights and financial results for the third quarter 2023

-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative...

November 3, 2023, 11:00 am

Anaptys to present phase 1 data on anb032, its btla agonist antibody, at the 32nd eadv congress

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative ...

October 11, 2023, 9:15 am

Vivos therapeutics to kick off clinical trial at stanford medicine

Vivos Therapeutics (NASDAQ:VVOS) Inc has announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford ...

October 11, 2023, 8:29 am

Morphic to present positive emerald-1 phase 2a data for morf-057 in patients with moderate to severe ulcerative colitis in abstract for uegw 2023

-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-...

September 22, 2023, 9:30 pm

Morphic to present positive emerald-1 phase 2a data for morf-057 in patients with moderate to severe ulcerative colitis in abstract for uegw 2023

-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-...

September 22, 2023, 5:30 pm

Teva pharmaceutical's remarkable growth in 2023: a success story

On August 2, 2023, Teva Pharmaceutical, one of the world's top generic drug manufacturers, will publish its financial report for the second quarter of...

July 20, 2023, 10:43 am

Valeo pharma says health canada has accepted for review veru's new drug submission for sabizabulin

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said that Health Canada has accepted for review Veru's New Drug Submission (NDS-CV) for sabizabulin for COVI...

January 26, 2023, 8:00 am

Celularity’s placental-derived allogeneic cell therapy provides clinically meaningful benefit and durable biological effect in patients with moderate to severe crohn’s disease in phase 1, phase 1b/2a

Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support...

January 6, 2023, 1:10 pm

Celldex (cldx) down on interim data from phase ib study in csu

Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate t...

July 4, 2022, 1:12 pm

Can-fite biopharma shares jump after piclidenoson data in psoriasis trial

Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with ...

June 29, 2022, 7:57 am

Concert pharmaceuticals: a balanced risk/reward

Concert Pharmaceuticals has a JAK inhibitor for alopecia areata (AA) that may be superior to competitive products. The company cites a figure of 1.5m ...

June 15, 2022, 11:48 am

What's going on with myovant sciences stock today?

Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on ...

April 12, 2022, 9:32 am

Could this new indication create a blockbuster for pfizer?

Cibinqo was approved in the U.S. to treat patients with moderate to severe eczema....

February 5, 2022, 6:45 am

Could this new indication create a blockbuster for pfizer?

Cibinqo was approved in the U.S. to treat patients with moderate to severe eczema....

February 5, 2022, 6:45 am

Could this new indication create a blockbuster for pfizer?

Cibinqo was approved in the U.S. to treat patients with moderate to severe eczema....

February 5, 2022, 6:45 am

Abbvie: skyrizi and rinvoq latest fda approvals bode well for humira patent loss

Recent FDA approval for Skyrizi was obtained for the treatment of adults with active psoriatic arthritis. Another recent FDA approval was for Rinvoq, ...

January 25, 2022, 1:32 pm

Abbvie: skyrizi and rinvoq latest fda approvals bode well for humira patent loss

Recent FDA approval for Skyrizi was obtained for the treatment of adults with active psoriatic arthritis. Another recent FDA approval was for Rinvoq, ...

January 25, 2022, 1:32 pm

Abbvie: skyrizi and rinvoq latest fda approvals bode well for humira patent loss

Recent FDA approval for Skyrizi was obtained for the treatment of adults with active psoriatic arthritis. Another recent FDA approval was for Rinvoq, ...

January 25, 2022, 1:32 pm

Bristol myers (bmy) uc candidate fails in phase ii study

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate t...

October 8, 2021, 10:20 am

Bristol myers (bmy) uc candidate fails in phase ii study

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate t...

October 8, 2021, 10:20 am


Search within

Pages Search Results: